FDA seeks feedback on digital tools for diabetes
pharmaphorum
JANUARY 14, 2024
FDA has opened a comment period until January 31 on how digital health technologies (DHTs) may be deployed to help prevent, detect and manage diabetes
pharmaphorum
JANUARY 14, 2024
FDA has opened a comment period until January 31 on how digital health technologies (DHTs) may be deployed to help prevent, detect and manage diabetes
Drug Patent Watch
JANUARY 14, 2024
Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are fourteen… The post New patent expiration for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
JANUARY 14, 2024
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development.
Drug Patent Watch
JANUARY 14, 2024
Annual Drug Patent Expirations for SECUADO Secuado is a drug marketed by Hisamitsu and is included in one NDA. It is available from one supplier. There are five patents protecting… The post New patent for Hisamitsu drug SECUADO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 14, 2024
Annual Drug Patent Expirations for AUGTYRO Augtyro is a drug marketed by Bristol and is included in one NDA. It is available from one supplier. The generic ingredient in AUGTYRO… The post New patent for Bristol drug AUGTYRO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 14, 2024
Annual Drug Patent Expirations for EPRONTIA Eprontia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are two patents protecting… The post New patent for Azurity drug EPRONTIA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JANUARY 14, 2024
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs… The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Let's personalize your content